Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

• Status: Not yet recruiting
• Trial end date: 2026-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the rate and severity of cytokine release syndrome (CRS) and neurologic events following outpatient administration of axicabtagene ciloleucel in participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kite, A Gilead Company
• Treatments: Cyclophosphamide; Dexamethasone; Fludarabine

Criteria

Key Inclusion Criteria:

• Histologically confirmed large B-cell lymphoma (LBCL), including the following types defined by World Health Organization (WHO) 2016 classification, by local pathology laboratory assessment, are eligible as defined below:

• Diffuse large B-cell lymphoma (DLBCL) not otherwise specified.

• High-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 and/or BCL6 rearrangement.

• DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV) + DLBCL.

• Primary mediastinal (thymic) LBCL.

• Primary cutaneous DLBCL, leg type.

• Transformation of follicular lymphoma to DLBCL will also be included.

• Relapsed or refractory disease after first-line chemotherapy.

• Individuals must have received adequate prior therapy including:

• Anti-CD20 monoclonal antibody AND

• An anthracycline-containing chemotherapy regimen.

• At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Individual agrees to outpatient treatment setting and to adhere to the prespecified clinical monitoring requirements.

Key Exclusion Criteria:

• Received more than 1 line of therapy for LBCL.

• History of autologous or allogeneic stem cell transplant.

• Prior cluster of differentiation (CD)19 targeted therapy.

• Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.

• Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite medical monitor.

• Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma. DLBCL epidural involvement should be considered as positive CNS disease.

• In the investigator's judgment, the individual is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.